172 related articles for article (PubMed ID: 31801177)
1. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
[TBL] [Abstract][Full Text] [Related]
2. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
Chen Y; Lairson DR; Chan W; Du XL
Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
[TBL] [Abstract][Full Text] [Related]
3. Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China.
Bao L; Liu AJ; Chu B; Wang Q; Dong YJ; Lu MQ; Shi L; Gao S; Wang YT; Wang LF; Chen WM; Zhuang JL
Cancer Med; 2023 Feb; 12(3):3101-3111. PubMed ID: 36271592
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Hernández-Rivas JÁ; Arnao M; Arguiñano Pérez JM; Rubio A; García EG; de Miguel D; Cherepanov D; Romanus D; Verleger K; Johnson C; Corman SL; Grande M; Persona EP
Future Oncol; 2021 Sep; 17(26):3465-3476. PubMed ID: 34342494
[TBL] [Abstract][Full Text] [Related]
5. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
6. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
7. Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Leng S; Chen Y; Tsai WY; Bhutani D; Hillyer GC; Lim E; Accordino MK; Wright JD; Hershman DL; Lentzsch S; Neugut AI
J Natl Compr Canc Netw; 2019 Jan; 17(1):22-28. PubMed ID: 30659126
[No Abstract] [Full Text] [Related]
8. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.
Ailawadhi S; Frank RD; Sharma M; Menghani R; Temkit M; Paulus S; Khera N; Hashmi S; Advani P; Swaika A; Paulus A; Aslam N; Sher T; Roy V; Colon-Otero G; Chanan-Khan A
Cancer; 2018 Apr; 124(8):1710-1721. PubMed ID: 29360160
[TBL] [Abstract][Full Text] [Related]
9. Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.
Braunlin M; Belani R; Buchanan J; Wheeling T; Kim C
Leuk Lymphoma; 2021 Feb; 62(2):377-386. PubMed ID: 33026271
[TBL] [Abstract][Full Text] [Related]
10. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW; Milton DR; Delgado R; Shah N; Patel K; Nieto Y; Kebriaei P; Popat UR; Parmar S; Oran B; Ciurea S; Hosing C; Lee HC; Manasanch E; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH; Bashir Q
Cancer; 2017 Sep; 123(18):3568-3575. PubMed ID: 28513828
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
12. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
Olszewski AJ; Barth PM; Reagan JL
Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
15. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Pérez R; Durán MS; Mayans J; Soler A; Castillo I; Jurado M; Ribas P; Menchaca Echevarria MC; Hernandez MT; Lopez Garcia-Carreño MD; Echeveste Gutierrez A; Bailen Garcia A; Lopez S; Baquero J; Ramirez G
Eur J Haematol; 2016 Apr; 96(4):417-24. PubMed ID: 26190662
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
18. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
Shaw J; Harvey C; Richards C; Kim C
Leuk Lymphoma; 2019 Dec; 60(13):3235-3243. PubMed ID: 31185769
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
20. Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.
Koff JL; Rai A; Flowers CR
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e115-e121. PubMed ID: 29273217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]